*September 2025*
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, joined Lung Cancers Today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) to discuss an update on the HARMONi study.
Note to reader: This drug combination is for second-line treatment after progression on Osimertinib. Keep in mind that the progression free survival (PFS) for Ivonescimab and Osimertinib was 6.8 months vs 4.4 months for chemotherapy and placebo, a difference of only 2.4 months. The overall survival (OS) for the drug combination was 16.8 vs 14 months for chemotherapy and placebo, a difference of +2.8 months.
